Top Page
China Isotope & Radiation Corp.
(1763)
China Isotope & Radiation Corp. (1763) vs. iShares MSCI Hong Kong ETF (EWH)
China Isotope & Radiation Corp. Business Overview & Revenue Model
China Isotope & Radiation Corp. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.62B | 7.57B | 6.63B | 6.15B | 5.14B | 4.27B |
| Gross Profit | 3.68B | 3.68B | 3.48B | 3.51B | 3.24B | 2.62B |
| EBITDA | 1.34B | 1.28B | 1.22B | 1.05B | 901.43M | 717.43M |
| Net Income | 424.14M | 406.64M | 370.97M | 392.27M | 335.75M | 213.58M |
Balance Sheet | ||||||
| Total Assets | 15.65B | 14.77B | 13.19B | 11.69B | 10.47B | 9.19B |
| Cash, Cash Equivalents and Short-Term Investments | 2.69B | 2.63B | 2.94B | 2.93B | 2.79B | 2.59B |
| Total Debt | 3.02B | 2.57B | 1.70B | 903.86M | 856.63M | 749.64M |
| Total Liabilities | 7.69B | 7.02B | 6.05B | 5.13B | 4.44B | 3.68B |
| Stockholders Equity | 5.08B | 5.01B | 4.69B | 4.47B | 4.18B | 3.89B |
Cash Flow | ||||||
| Free Cash Flow | -766.49M | 142.48M | -812.66M | 328.66M | 366.59M | -118.01M |
| Operating Cash Flow | 14.07M | 142.48M | 84.96M | 862.66M | 794.31M | 291.91M |
| Investing Cash Flow | -347.00M | -564.81M | -429.88M | -506.62M | -907.36M | -423.90M |
| Financing Cash Flow | 608.94M | 499.70M | 484.37M | -291.50M | -97.44M | -156.25M |
China Isotope & Radiation Corp. Technical Analysis
China Isotope & Radiation Corp. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$7.13B | 15.57 | 8.59% | 2.76% | 13.59% | 6.31% | |
69 Neutral | HK$6.46B | 20.18 | 11.24% | 1.26% | 25.18% | 55.79% | |
69 Neutral | HK$9.56B | 20.24 | 8.69% | 1.88% | 14.56% | 61.60% | |
58 Neutral | HK$8.29B | 46.97 | 4.99% | 0.48% | 35.01% | 483.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$5.54B | 386.36 | 0.22% | ― | -4.38% | ― |
China Isotope & Radiation Corp. Corporate Events
China Isotope & Radiation Corporation announced that shareholders at its first extraordinary general meeting of 2026 approved a series of renewed framework agreements governing products and services supply, products and services purchase, engineering construction services, and financial services, all with proposed annual caps. Despite CNNC and its associates abstaining from voting due to material interests in these connected transactions, all four ordinary resolutions were passed by poll—three with unanimous support and the financial services framework with more than 92% approval—thereby providing formal shareholder backing for the continuation of key related-party arrangements that underpin the company’s ongoing operations and financing structure.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$26.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation has disclosed that its non-wholly-owned subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., has been ordered by Chinese tax authorities to pay RMB188 million in additional corporate income tax, value-added tax and other taxes for the period from 1 January 2021 to 31 December 2024, plus late payment surcharges, bringing the total tax settlement to RMB271 million. The tax adjustment, which centers on sales expenses and abnormal inventory losses at Headway and carries no administrative penalties, has already been fully paid and is expected to reduce the company’s profit attributable to equity shareholders in 2025 by about RMB130 million, with final impact subject to independent audit review; the company says it will strengthen internal management and warns investors to exercise caution as it may issue further updates.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$25.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation announced that its subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech, has received approval from China’s National Medical Products Administration to begin clinical trials for its independently developed BNCT boron drug, Borofalan (10B) for Injection. The drug is designed for difficult-to-treat head and neck tumors that are resistant to conventional radiotherapy and chemotherapy, offering a short treatment course of one to two sessions with low toxicity and side effects, reflecting a cutting-edge approach in precision oncology. The clinical trial approval represents a key milestone in Zhonghe Headway’s integrated drug-device BNCT program, moving the project into the clinical translation phase and strengthening CIRC’s position in advanced nuclear medicine while aligning with China’s broader “Healthy China” strategy and ambitions to provide a domestic, globally relevant solution for tumor treatment.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$25.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation has called its first extraordinary general meeting of 2026 for 9 January in Beijing, where shareholders will vote on renewing a series of key framework agreements covering products and services supply, products and services purchase, engineering construction services and financial services, each with proposed new annual caps. The meeting arrangements detail eligibility, share registration closure, and proxy procedures, underscoring the importance of these related operational and financial agreements for the company’s ongoing business activities and governance, and giving shareholders a formal opportunity to approve or reject the terms that will shape its commercial and funding relationships in the coming years.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$25.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation has announced a commercial cooperation agreement between its subsidiary HTA Co., Ltd. and Novartis Pharma Technology (Zhejiang) Co., Ltd. This agreement focuses on Pluvicto®, a prostate-specific membrane antigen-targeted radioligand therapy for advanced prostate cancer. The collaboration aims to leverage HTA’s experience in radiopharmaceuticals to supply Pluvicto® and related solutions, enhancing treatment options and improving patient outcomes in the PRC.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$25.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation announced the renewal of several key agreements, including supply, purchase, leasing, and financial services frameworks, for a term of three years starting from December 2025. These agreements are subject to approval by independent shareholders and are considered fair and reasonable by the company’s directors. The transactions are part of the company’s ordinary business operations and are expected to have implications for its market positioning and stakeholder interests, given their scale and the involvement of the controlling shareholder, CNNC.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$25.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation (CIRC) has entered into a strategic cooperation agreement with CNNC Capital Holdings Limited to enhance the integration of the nuclear technology application industry chain. This collaboration aims to overcome technological bottlenecks and foster new productive forces through mergers, acquisitions, and equity investments, thereby empowering CIRC with financial capital for high-quality development.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$25.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation has announced its first export of self-produced irradiation equipment to the Latin American market, specifically to a Peruvian client for an Agricultural Gamma Irradiation Station Project. This project, aligned with the Belt and Road Initiative and the IAEA’s ‘Atoms for Food’ initiative, aims to improve the sterilization and shelf life of agricultural products, enhancing their market competitiveness. It also represents a step forward in China-Peru nuclear technology cooperation, potentially opening new global opportunities for China’s nuclear technology sector.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$25.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation has signed an agreement with Brazil’s National Nuclear Energy Commission to supply cobalt-60 radioactive sources for irradiation purposes. This marks CIRC’s first export of self-produced cobalt-60 to the Latin American market, enhancing Brazil’s irradiation capacity and promoting the benefits of irradiation technology in various fields.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$25.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation announced that its subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., has been recognized as a National-Level Manufacturing Enterprise and awarded the ‘Single-Item Champion in the Pharmaceutical Industry’ for its Urea [13C/14C] Breath Test Kits. This accolade underscores CIRC’s leading position in the breath diagnostic sector and its commitment to innovation and expanding its product offerings to enhance national health defenses.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
CIRC has announced a significant technological breakthrough in the production of carbon isotope products, specifically high-abundance 13CO gas, which is crucial for urea breath tests detecting Helicobacter pylori infections. This advancement positions China among the few countries capable of producing these materials, reducing reliance on imports and enhancing the nation’s research and production capabilities in stable isotope technology. Additionally, CIRC has started phase II construction of its stable isotope base project, which will ensure a stable supply of these materials, contributing to public health improvements and supporting the Healthy China Initiative.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation has been recognized for its exemplary ESG practices, receiving the Outstanding China ESG Practice and ESG Pioneers Index (Top 100) awards at the ESG China Innovation Annual Conference 2025. The company’s focus on technological innovation and sustainable development has led to significant advancements in nuclear technology applications, contributing to economic, environmental, and social benefits while supporting China’s health initiatives.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$19.50 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation announced the successful results of its Extraordinary General Meeting (EGM) held on October 17, 2025. Key resolutions approved included the appointment of a domestic auditor for 2025 and the declaration of an interim dividend of RMB0.0807 per share for the first half of 2025. This decision reflects the company’s commitment to shareholder returns and may enhance its market positioning by demonstrating financial stability and operational transparency.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation has announced an updated interim dividend for the six months ending June 30, 2025, with a declared dividend of RMB 0.0807 per share. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.09528, with the payment date set for December 31, 2025. The announcement includes details on withholding tax rates applicable to non-resident shareholders, which vary based on their country of residence and existing tax treaties with China. This update reflects the company’s commitment to shareholder returns and provides clarity on the financial implications for international investors.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation’s subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., has submitted an IND application for its innovative BNCT boron drug, ‘Borofalan (10B) for Injection,’ which has been accepted by the National Medical Products Administration. This development marks a significant breakthrough in China’s BNCT technology, enhancing precision tumor treatment and contributing to global oncology advancements.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation has announced the launch of a new isotope separation technology called the ‘Adsorption Trapper’ by its subsidiary, Chengdu Gaotong Isotope Co., Ltd. This innovative technology utilizes fourth-generation MOF materials to enhance nuclear medicine and nuclear fusion development, offering high purity and efficiency at a lower cost. The advancement is expected to significantly impact the national economy by supporting key areas such as nuclear medicine and biomedical research, while also reducing China’s reliance on imported high-end isotopes.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation (CIRC) has signed a Memorandum of Understanding with Brazil’s National Commission for Nuclear Energy to establish a long-term cooperation mechanism. This partnership aims to enhance isotope product supply, quality management, and information exchange, supporting Brazil’s nuclear technology and radiopharmaceutical industries. The agreement is expected to help CIRC expand its international cooperation, promote its technologies, and contribute to the peaceful uses of nuclear technology.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.